Evidence map›Paper›PMID 37160925›Full record

ArticleScientific reports2023

HCV, HIV AND HBV rapid test diagnosis in non-clinical outreach settings can be as accurate as conventional laboratory tests.

Milagros Muñoz-Chimeno, Jorge Valencia, Alvaro Rodriguez-Recio, Guillermo Cuevas, Alejandra Garcia-Lugo, Samuel Manzano, Vanessa Rodriguez-Paredes, Beatriz Fernandez, Lucía Morago, Concepción Casado and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Milagros Muñoz-Chimeno *Hepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.
Jorge Valencia *Infanta Leonor Hospital, Madrid, Spain.
Alvaro Rodriguez-RecioHepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.
Guillermo CuevasInfanta Leonor Hospital, Madrid, Spain.
Alejandra Garcia-LugoHepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.
Samuel ManzanoInfanta Leonor Hospital, Madrid, Spain.
Vanessa Rodriguez-ParedesHepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.
Beatriz FernandezInfanta Leonor Hospital, Madrid, Spain.
Lucía MoragoHepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.
Concepción CasadoMolecular Virology Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain.
Ana AvellónHepatitis Unit, National Center of Microbiology, Carlos III Institute of Health, Madrid, Spain. aavellon@isciii.es.
Pablo RyanInfanta Leonor Hospital, Madrid, Spain. pablo.ryan@salud.madrid.org.
Instituto de Salud Carlos III · ESHospital Universitario Infanta Leonor · ESCentre for Biomedical Network Research on Rare Diseases · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Point of care rapid diagnostic tests (POC-RDT) for Hepatitis C virus (HCV), Human Immunodeficiency virus (HIV) and Hepatitis B virus (HBV), are ideal for screening in non-clinical outreach settings as they can provide immediate results and facilitate diagnosis, allowing high risk population screening. The aim of this study was to compare POC-RDT with laboratory conventional tests. A total of 301 vulnerable evaluable subjects (drug users, migrants and homeless population) were recruited at a mobile screening unit in outreach settings in Madrid. Fingerprick whole blood capillary samples were tested using the SD BIOLINE HCV POC-RDT, Determine HIV Early Detect and Determine HBsAg 2, and the results were assessed against the LIAISON XL HCV, HIV and Murex-HBsAg-Quant, reference assays, respectively. The feasibility and user satisfaction of the POC-RDT were evaluated through a questionnaire. The resolved sensitivity and resolved specificity and their 95% confidence intervals (95% CI) were as follows, respectively: SD-BIOLINE-HCV: 98.8% (95% CI 93.4, 100.0) and 100.0% (95% CI 98.3, 100.0); Determine HIV Early Detect: 100% (95% CI 85.2, 100.0) and 100% (95% CI 98.7, 100); and Determine HBsAg 2: 66.7% (95% CI 9.4, 99.2) and 100.0% (95% CI 98.7, 100.0). As expected, the number of subjects with a confirmed positive result for HBsAg was very low (n = 4). Therefore, the analytical sensitivity has been evaluated in addition: The Determine HBsAg 2 test demonstrated 100% sensitivity for standard concentrations ≥ 0.125 IU/mL. The subject questionnaire yielded positive feedback for most subjects. The POC-RDT fingerprick blood collection method was well received, and the tests demonstrated a comparable clinical performance with conventional tests in outreach settings and vulnerable high-risk populations.

Indexed as

Hepatitis CHIV InfectionsHepacivirusHepatitis B Surface AntigensHepatitis B virusHIVHumansHepatitis B Surface Antigens

Identifiers

PMID37160925
PMCPMC10170094
OpenAlexW4376133767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.